Turin Study Maps Why Multiple Myeloma Escapes Anti-CD38 Immunotherapy
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
Latest breakthroughs in cancer research, treatment, and prevention
643 articles
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
NCI-sponsored trial tests whether adding nivolumab to ipilimumab improves outcomes in stage III/IV unresectable melanoma.
A landmark Cell study reveals that the patient's own immune system—not just CAR T cells—decides outcomes in recurrent glioblastoma.
A comprehensive review reveals how combining genomics, proteomics, and metabolomics is uncovering new AML targets and improving patient outcomes.
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
A Columbia University trial tested a digital care service to improve immunotherapy outcomes and reduce healthcare burden for minority lung cancer patients.
Peter Attia breaks down why standard screening guidelines fall short and how to build a personalized, risk-based breast cancer detection plan.
A sweeping review of CAR-T and CAR-NK cell therapies in acute myeloid leukemia, covering clinical trial outcomes, key targets, and next-gen strategies.
A completed exploratory trial evaluates whether a specialized compression garment can reduce discomfort and improve quality of life in pelvic lymphedema patients.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.